secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indivior Pharmaceuticals, Inc. (INDV)
CIK:        0001625297
Form:       8-K
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0001193125-25-257381
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indivior Q3 net revenue $314M (+2% YoY); raises FY2025 guidance materially
--------------------------------------------------------------------------

- SUBLOCADE net revenue $219M (+15% YoY); U.S. SUBLOCADE up 14% to $203M.
- Adjusted EBITDA $120M (+14% YoY); non-GAAP diluted EPS $0.72 vs $0.49 YoY.
- FY2025 net revenue guidance raised to $1.18-1.22B; adjusted EBITDA now $400-420M.
- Plans to exit several ROW markets, discontinue OPVEE sales support, saving at least $150M annually from 2026.
- Cash and investments $473M at Q3 end, up $125M from year-end 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625297/000119312525257381/0001193125-25-257381-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625297/000119312525257381/d58033d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-257381

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer